Clearance Summary
Apollo ESG NXT System, Apollo REVISE NXT System received FDA 510(k) clearance under submission number K232544, sponsored by Apollo Endosurgery, Inc.. The device was reviewed via the Special premarket notification pathway and assigned to the Gastroenterology, Urology review panel. The statutory decision date of record is 2023-09-18.
- Submission: K232544
- Applicant / Sponsor: Apollo Endosurgery, Inc.
- Clearance pathway: Special
- Review panel: Gastroenterology, Urology
- Device class: Class II
- Regulation citation: 21 CFR 876.5983
- Decision date: 2023-09-18
Classification & Regulation
This clearance is catalogued under FDA product code QTD and 21 CFR 876.5983, within the Gastroenterology, Urology review panel as a Class II device.